Vemlidy’s active competition in chronic hepatitis B treatment market
Gilead Sciences’ ‘Vemlidy Tab’ has entered general hospitals one after another, which raises an expectation on its sales performance in the future.
‘Vemlidy,’ a Gilead Sciences’ chronic hepatitis B treatment whose health insurance benefit has started to be applied on both first and resistance pa...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.